S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:ASRT

Assertio (ASRT) Stock Price, News & Analysis

$0.99
-0.03 (-2.94%)
(As of 03/27/2024 ET)
Today's Range
$0.98
$1.06
50-Day Range
$0.79
$1.14
52-Week Range
$0.77
$8.01
Volume
3.29 million shs
Average Volume
1.32 million shs
Market Capitalization
$94.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Assertio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
455.6% Upside
$5.50 Price Target
Short Interest
Bearish
11.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Assertio in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$11,481 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.04) to $0.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

737th out of 939 stocks

Pharmaceutical Preparations Industry

344th out of 436 stocks

ASRT stock logo

About Assertio Stock (NASDAQ:ASRT)

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

ASRT Stock Price History

ASRT Stock News Headlines

Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Q4 2023 Assertio Holdings Inc Earnings Call
Recap: Assertio Holdings Q4 Earnings
The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
Assertio: Q4 Earnings Snapshot
ASRT Mar 2024 4.500 call
Assertio Holdings's Earnings: A Preview
Assertio 24 Hour Deadline Alert
Assertio 48 Hour Deadline Alert
Assertio Shareholder Notice
See More Headlines
Receive ASRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ASRT
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$7.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+455.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-331,940,000.00
Net Margins
-218.28%
Pretax Margin
-167.07%

Debt

Sales & Book Value

Annual Sales
$152.07 million
Cash Flow
$0.69 per share
Book Value
$1.46 per share

Miscellaneous

Free Float
87,495,000
Market Cap
$94.05 million
Optionable
Optionable
Beta
0.96
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

ASRT Stock Analysis - Frequently Asked Questions

Should I buy or sell Assertio stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASRT shares.
View ASRT analyst ratings
or view top-rated stocks.

What is Assertio's stock price target for 2024?

1 equities research analysts have issued twelve-month price targets for Assertio's stock. Their ASRT share price targets range from $4.00 to $7.00. On average, they predict the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 455.6% from the stock's current price.
View analysts price targets for ASRT
or view top-rated stocks among Wall Street analysts.

How have ASRT shares performed in 2024?

Assertio's stock was trading at $1.07 at the start of the year. Since then, ASRT stock has decreased by 7.5% and is now trading at $0.99.
View the best growth stocks for 2024 here
.

Are investors shorting Assertio?

Assertio saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 10,730,000 shares, an increase of 9.5% from the February 29th total of 9,800,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is presently 9.8 days.
View Assertio's Short Interest
.

When is Assertio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ASRT earnings forecast
.

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) posted its earnings results on Thursday, November, 4th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.12. The business had revenue of $25.47 million for the quarter, compared to analysts' expectations of $22.04 million. Assertio had a positive trailing twelve-month return on equity of 6.30% and a negative net margin of 218.28%. During the same quarter last year, the business earned ($0.36) EPS.

What ETF holds Assertio's stock?

Hartford Multifactor Small Cap ETF holds 43,843 shares of ASRT stock, representing 0.64% of its portfolio.

What guidance has Assertio issued on next quarter's earnings?

Assertio updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $110.0 million-$125.0 million, compared to the consensus revenue estimate of $160.6 million.

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK).

Who are Assertio's major shareholders?

Assertio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (8.05%), Armistice Capital LLC (6.13%), Vanguard Group Inc. (5.15%), Vanguard Group Inc. (5.15%), Goldman Sachs Group Inc. (1.25%) and Goldman Sachs Group Inc. (1.25%). Insiders that own company stock include Ajay Patel, Daniel A Peisert, Heather L Mason, James L Tyree, Paul Schwichtenberg, Sam Schlessinger and William Mckee.
View institutional ownership trends
.

How do I buy shares of Assertio?

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASRT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners